Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Loading...
Most Recent Stories

JP MORGAN STRATEGY UPDATE – ASSET REFLATION IS TAKING OVER

JP Morgan remains firmly in the bull camp despite a downtick in their economic surprise index and what they refer to as a “more challenging” downturn in stocks.  Despite this, they see earnings season coming to the rescue as stocks face a more challenging economic data backdrop:

  • Portfolio strategy: The recovery trade may seem a bit wobbly, but the asset reflation trade––dumping zeroreturn cash for any other asset––is making up the difference. Stay long equities and credit.
  • Economics: 3Q is tracking light, but not enough to change forecasts.

jpm1

  • Fixed Income: Trade the range. We go short in USTs.
  • Equities: Take profit on Cyclicals overweight in Europe, moving to neutral.
  • Credit: Credit requires only moderate economic growth, and investor demand remains strong. Stay long in both HG and HY in the US.
  • FX: Focus on currencies of under-owned equity markets.
  • Alternatives: Hedge funds were up 2% last month.  Favor Convertible Arb and Equity Long-Short.

JPM has nailed the reflation trade and they continue to believe it has legs:

Our overall strategy has two legs––the recovery and asset reflation. The latter is a fancy name for capital flowing out of cash, in response to zero cash returns and falling market uncertainty. The recovery trade may be a bit wobbly this month, but asset reflation is gathering strength.  The asset class that benefits most here is clearly credit. This is why credit spreads started rallying early this year, still in the midst of the Great Recession. We stay long, even as
spreads have collapsed and are below peak recession levels.

The next catalyst for a rise in stocks is the coming earnings season:

Equities are entering October in wait-and-see mode, with all eyes on the upcoming US 3Q earnings season. Indications are that US earnings should move up from 2Q, as
top-lines should grow in line with a rebound in the broad economy, while companies remain in cost-cutting mode. Most market participants expect 3Q earnings to beat analysts’ forecasts, but clearly it cannot be that “everyone expects everyone (else) to be surprised.” That said, we remain optimistic that strong sequential earnings growth, even if not a surprise to everyone, will support equity markets during 4Q.

Near term, the major driver for equities is likely to be the 3Q reporting season that kicks off next week. Strong 4% real GDP growth in the US in 3Q and a surge in global IP set the stage for another positive surprise, relative to analysts’ expectations. Cyclical sectors are likely to drive this upward surprise, and we thus stay overweight versus Defensives in the US.

Although I am less optimistic than JPM about the long-term sustainability of the recovery it is difficult not to agree with their near-term prognosis for earnings and the market.

Source: JPM